AdaptHealth Corp. (AHCO): what the price assumes

boothcheck covers AdaptHealth Corp. (AHCO) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/AHCO

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 9: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.8% sits below it).

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is supported by asset-based value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.5%); the inversion above states its own rate.

Per-Model Detail (n=3)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.6%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• About a third of revenue arrives as fixed monthly equipment rental and most of the rest as resupply, since "Net sales revenue consists of revenue recognized at a point in time for the sale of supplies and consumables" that chronically ill patients reorder on a clinical schedule rather than a discretionary one.
• Borrowings, not operations, govern what the equity is worth: the term loan came down to "$315.0 million" at the end of 2025 from "$550.0 million" a year earlier, sitting alongside "$1,435.0 million aggregate principal amount of unsecured senior notes outstanding."
• AdaptHealth agreed on July 19 to sell its Diabetes Health business to Cardinal Health for $235 million in cash, and reports second-quarter results on August 4.

Bull Case

One number decides this investment, and it is not a revenue line. It is the debt. A company with an equity value near $1.5 billion is carrying "$1,435.0 million aggregate principal amount of unsecured senior notes outstanding" plus a term loan, which means the lenders and the owners are dividing up a business of roughly $3.3 billion in revenue and the split is currently tilted heavily toward the lenders. Every dollar of principal retired moves across that line to the owner, and it does so without a single new patient, a single new contract or a single point of margin.

Management is doing exactly that. In 2025 the company made "voluntary repayments on the 2024 Term Loan totaling $ 218.8 million", taking the balance from "$550.0 million" to "$315.0 million" in twelve months. Voluntary is the important word. This was not a scheduled amortization the credit agreement forced; it was free cash flow directed at the capital structure instead of at acquisitions, which is a marked change of habit for a company that spent its earlier years buying competitors.

The July agreement pushes the same lever harder. Cardinal Health will acquire the Diabetes Health business for $235 million in cash. Set that against an equity of this size and it is not a rounding item. It is a meaningful slug of proceeds arriving at a business whose share price moves on the ratio of debt to earnings more than on anything else, and it comes from selling the segment furthest from the company's core competence.

What remains is more durable than the phrase durable medical equipment suggests. The Respiratory Health segment "provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure." Chronic is the operative word. A patient on home oxygen does not stop needing oxygen when the economy softens, and the equipment side of the business bills as "revenue recognized over the" month rather than as a one-time sale. Roughly a third of revenue behaves that way, and the resupply consumables behave similarly, because a CPAP mask and its tubing wear out on a schedule.

The newest piece is a genuine change in shape. In the March quarter the company completed the largest capitated transition in the history of home medical equipment, onboarding more than 10 million new members and standing up 35 de novo locations across eight states, with revenue per member and utilization metrics tracking to plan and full-year revenue guidance raised by $10 million on the strength of it. Capitated arrangements are the smallest of the three revenue lines today at roughly 4%. After a transition of that size, that mix does not stay where it is, and capitation trades the endless fee-for-service billing fight for a fixed payment per member and the incentive to manage the population well.

Bear Case

AdaptHealth just told the market where the money is in one of its businesses, by agreeing to sell it. The Diabetes Health segment distributes continuous glucose monitors and pumps made by other people. Look at what those other people earn. DexCom keeps 61.5 cents of gross profit on every revenue dollar and converts 21.4 cents into operating profit; Insulet keeps 71.0 cents and converts 17.5. AdaptHealth, taking those same devices, handing them to patients and arguing with payers about them, turns roughly 5.3 cents of the revenue dollar into operating profit across the whole company. Selling the segment to Cardinal Health for $235 million is the correct decision and also a confession about the industry structure: in connected devices, the manufacturer takes the economics and the distributor takes the paperwork.

Nothing about that structure is confined to diabetes. The price of almost everything AdaptHealth sells is set by its largest customer, and that customer runs an auction. On the bidding program for durable medical equipment, the 10-K says the company "cannot predict the outcome of the DMEPOS Competitive Bidding Program on its business in the future nor the Medicare payment rates that will be in effect in future years for the items subjected to competitive bidding, the program may materially adversely affect its financial condition and" results. Elsewhere it flags the same exposure on the diabetes side, warning what happens "If CMS pursued payment reductions to Medicare's payment rates for CGMs and supplies." A business whose selling price is decided by a government auction has a ceiling that no amount of operational excellence lifts.

The sleep franchise, which is the piece most investors think of first, is already going the wrong way. The 10-K attributes part of the year's revenue movement to "a decrease in net revenue from fixed monthly equipment reimbursements from lower sleep rental products", and on the segment's own adjusted profit measure, Sleep Health "decreased by $38.2 million or 10.9%, for the year ended December 31, 2025 compared to the year ended December 31, 2024." Sleep is where the CPAP business lives, and a double-digit decline in its profitability is not a rounding difference in a company this thinly profitable.

Which brings the growth arithmetic into focus. Organic revenue grew "1.7 %" in 2025. The current price needs company-wide operating profit to compound at roughly 4.4% a year. If volume is growing at not much more than inflation and the price per unit is set in an auction, the difference has to come out of costs, and it has to keep coming out of costs indefinitely. That is a demanding ask of a business that also just reported the March quarter's adjusted profit measure falling about $7 million short of its own guidance on $12 million of elevated labor costs during the capitated onboarding.

Leverage is what makes all of it consequential rather than merely disappointing. Against those thin operating margins sit "$1,435.0 million aggregate principal amount of unsecured senior notes" and a term loan, under a credit agreement whose "Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Interest Coverage Ratio." The company also lost money on a net basis over the trailing twelve months. At about 5 cents of operating profit per revenue dollar, a two-point reimbursement cut does not trim earnings; it removes a large share of them, and the covenant conversation follows.

The concession is that management is behaving correctly in every visible way. It is paying down debt voluntarily, selling the business it is worst placed to own, and it executed a ten-million-member onboarding that most competitors could not attempt. The bear case is not about management. It is that the equity in a highly levered, low-margin business is a thin residual sitting underneath a payer who sets prices by auction, and that residual can be revalued by a policy decision the company has no part in.

Valuation

Equity on the books amounts to $11.10 for every share outstanding, and owners are paying a shade under that. Start there, because it is the whole framing: the market is currently crediting the assets and essentially nothing else. For a business generating $3.3 billion of revenue with a national delivery footprint, that is a statement about what the market thinks the earnings on those assets are worth, not about what the assets cost.

What the price does ask for is modest in isolation and hard in context. The multiple works out to roughly 20 times company-wide operating profit, which implies operating profit compounding at about 4.4% a year. Judged against what this company has recently delivered, that is unremarkable. The difficulty is the starting line: organic revenue rose "1.7 %" in 2025, so profit growth at more than twice that rate has to be manufactured out of margin, and margin is set across a table from Medicare rather than in a pricing meeting.

The methods arrange themselves in a pattern worth reading carefully. Book-value approaches land essentially on top of the price. Peer multiples land well above it. The earnings-based read lands below. That combination is the signature of a levered, low-margin operator: the assets are worth what they are worth, comparable companies in adjacent healthcare businesses trade at multiples this one cannot support on its current profitability, and the earnings themselves are too thin and too encumbered to reach the price on their own. The disagreement between those frames is not noise. It is the market saying it will pay for the balance sheet and wait on the income statement.

The cohort makes the reason explicit. Option Care Health, the closest comparable in scale for home-based care, converts about 5.8 cents of every revenue dollar into operating profit; Addus HomeCare about 9.8 and Aveanna about 10.9. AdaptHealth at roughly 5.3 sits at the bottom of that group. On growth the gap runs the same direction, with Addus up 19.6% and Aveanna 20.5% year over year against AdaptHealth's low single-digit organic pace. Slowest growth and thinnest profitability in the peer set is a coherent explanation for a valuation at book value, and it means the rerating case rests on changing one of those two things.

Which is why the capital structure, rather than the revenue line, is where this resolves. The 2024 Term Loan came down to "$315.0 million" from "$550.0 million" over 2025 through "voluntary repayments on the 2024 Term Loan totaling $ 218.8 million", and "$1,435.0 million aggregate principal amount of unsecured senior notes" remains outstanding. The $235 million of cash coming from the Cardinal Health sale continues that work. In a business where the equity is the thin slice left after the lenders, arithmetic on the debt moves the owner's stake faster than anything happening in the warehouses.

Catalysts

The largest near-term item is already signed. On July 19, 2026, AdaptHealth entered a definitive agreement to divest its Diabetes Health business to Cardinal Health for $235 million in cash, subject to customary purchase price adjustments. Two things follow from that and they point in opposite directions: the remaining company is smaller and more concentrated in sleep and respiratory, and it has cash to apply against borrowings that currently dominate its equity story.

Second-quarter results arrive before the market opens on Tuesday, August 4, with a call at 8:30 that morning. The specific thing to check is a promise management already made. The March quarter's adjusted profit measure came in roughly $7 million below guidance on about $12 million of elevated labor costs incurred during the rapid capitated patient transition, and management said those costs should normalize by the end of the second quarter. August 4 is when that claim gets tested.

The capitated ramp is the third thread and the one with the longest tail. The company onboarded more than 10 million new members and opened 35 de novo locations across eight states, and reported that revenue per member and utilization were tracking as expected, which supported a $10 million increase to full-year revenue guidance. Utilization is the number that decides whether capitation is a better business than fee-for-service or a worse one, and it takes several quarters of data before the answer is trustworthy.

Peer Cohorts (Per Segment, With Filing Citations)

Sleep Health / Respiratory Health / Wellness at Home (reported)

• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …us-gaap:GeographicConcentrationRiskMember adus:HomeHealthSegmentMember stpr:TN 2023-01-01 2023-12-31 0001468328 us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember us-gaap:GeographicConcentrationRiskMember adus:HomeHealthSegmentMember stpr:IL 2025-01-01 2025-12-31 0001468328…
• FY2025 10-K: …adus:HospiceSegmentMember adus:AllOtherStatesMember 2024-01-01 2024-12-31 0001468328 us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember us-gaap:GeographicConcentrationRiskMember adus:HospiceSegmentMember adus:AllOtherStatesMember 2023-01-01 2023-12-31 0001468328…
• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …wage, this has not historically been a source of risk to our margins, as our non-clinical reimbursement rates generally have mechanisms to adjust commensurate with state and local changes in applicable minimum wages. Pediatric Therapy We provide physical, occupational and speech therapy services to assist pediatric…
• FY2025 10-K: …following conditions: • Tracheotomies or ventilator dependence; • Dependence on continuous nutritional feeding through a "G-tube" or "NG-tube"; • Dependence on intravenous nutrition; • Oxygen-dependence in conjunction with other medical needs; and • Complex medical needs such as frequent seizures. PDN Services…
• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …and local levels places it in a strong position against existing and potential competitors. Intellectual Property Option Care Health and its subsidiaries own a variety of trademarks, licenses, and service marks, including but not limited to: "Option Care Health", "Option Care", "Critical Care Systems", "Clinical…
• FY2025 10-K: …infections in patients of all ages. The Company's anti-infective therapy and services help avoid hospitalizations for many infections that can be safely treated at home. • Nutrition Support. The Company delivers comprehensive nutrition support across pediatric, adult, and geriatric patients. The Company's expert team…

Diabetes Health (reported)

• DXCM (DEXCOM, INC.)
• FY2025 10-K: …In the future, we plan to expand our product offering to people who are pregnant and cleared/approved indications to address people with pre-diabetes, people who are obese, and people in the hospital setting. Although the majority of our revenue has been generated in the United States, we have expanded our operations…
• FY2025 10-K: …device, such as the Apple Watch and Wear OS by Google devices, when used in conjunction with the patient's or follower's compatible iPhone or Android mobile device. Data and Insulin Delivery Collaborations We have entered into multiple collaboration agreements that leverage our technology platform to integrate our…
• PODD (INSULET CORPORATION)
• FY2025 10-K: …or new generations of existing products, they may be quickly rendered obsolete by changing customer preferences, changing industry or regulatory standards, or competitors' innovations. Our failure to introduce commercially successful new and innovative products in a timely manner could have a material adverse effect…
• FY2025 10-K: …from MDI. Our distributors have also implemented virtual training programs. Customer Support We seek to provide our customers with high quality customer support, from product ordering to insurance investigation, order fulfillment, and ongoing support. Our customer support systems are integrated with our sales,…
• TNDM (Tandem Diabetes Care, Inc.)
• FY2025 10-K: …a new pump. These enhancements generally include new developments in our AID technology, CGM integrations and mobile app features. For more than a decade we have offered our customers, their caregivers and healthcare providers a data management application to provide a fast, easy and visual way to display diabetes…
• FY2025 10-K: …customer service and clinical resources; • greater ability to respond to competitive pressures, regulatory uncertainty, or challenges within the financial markets; • established relationships with healthcare providers, third-party payors and regulatory agencies; • established reputation and name recognition among…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.